Also known as: Egrifta
A GHRH analog that raises the body's own growth hormone. Approved to reduce belly fat in people with HIV.
Educational reference, not medical advice. Many compounds here are not approved, and products sold as research chemicals are not checked for purity. Plan any use with a licensed clinician.
How it works
Stimulates the pituitary to release growth hormone in natural pulses, which raises IGF-1 and targets visceral fat.
Evidence by goal
| Goal | Grade | What the grade means |
|---|---|---|
| Fat loss & weight | A | Approved for this use or large randomized trials |
| Blood sugar & metabolic | B | Human trials (smaller, mixed, or approved outside the US) |
| Muscle & growth hormone | B | Human trials (smaller, mixed, or approved outside the US) |
| Focus, memory & brain | B | Human trials (smaller, mixed, or approved outside the US) |
At a glance
- Route
- Subcutaneous daily
- Half-life
- About 30 minutes
Reported dosing
Label: 1.4 mg (Egrifta SV) or 2 mg daily.
Timing: Once daily; many clinicians prefer bedtime on an empty stomach to match the natural nighttime GH pulse.
Cycle: Continuous in trials (26 to 52 weeks). Benefits fade after stopping.
From approved labels where they exist, otherwise from published trials and practitioner reports.
Side effects
- Injection-site reactions
- Joint pain, fluid retention, numbness
- Raised blood sugar
Who should avoid it
- Pregnancy
- Active cancer
- Pituitary disorders or prior pituitary surgery
Often combined with
Sometimes paired with a GHRP such as ipamorelin in practitioner protocols.
Key findings
Reduced visceral fat about 15 to 18% in trials and reduced liver fat. A 2012 trial in older adults found better executive function.
Where it is legal (Oct 2026)
| US | Prescription |
|---|---|
| Canada | Prescription |
| Mexico | Not approved |
| EU | Not approved |
Sources
Open Tesamorelin in the Peptide Guide Compare all peptides by goal
Last reviewed November 2026. Regulatory status reflects the US unless noted and changes often.